The effect of 4% sodium cromoglicate cutaneous emulsion compared to vehicle in atopic dermatitis in children – A meta-analysis of total SCORAD scores

Journal of Dermatological Treatment, Ahead of Print.
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: article Source Type: research

Related Links:

Authors: von Csiky-Sessoms S Abstract A 42-year-old male with skin type I and a history of rosacea and eczema presented with crusting, erythema, and pustules distributed on the left oral commissure. Angular cheilitis was diagnosed and regular petrolatum use recommended until resolution of the lesion. Eight days later, with no improvement in symptoms, fungal and bacterial cultures were performed which resulted in the growth of cutibacterium acnes, a variant of p. acnes. PMID: 31524997 [PubMed - in process]
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
Authors: Ewy S, Pham H, Quan K, Su B, Tachdjian R Abstract Bullous pemphigoid (BP) is a rare blistering skin disease that is commonly treated with corticosteroids and immunosuppressive agents. Here, we present a 74-year-old woman with severe BP following a leg fracture who was successfully treated with omalizumab. We started her on a regimen of omalizumab 300 mg subcutaneously every 4 weeks, and within a week she reported significantly decreased pain and faster healing time of lesions. Incidentally, bilateral erythematous, non-blistering dermatitis developed 5 centimeters distal to the injection sites within a week...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
Authors: Tanis R, Ferenczi K, Payette M Abstract Prurigo nodularis (PN) is a disease in which chronic scratching and picking of the skin due to intense pruritis results in papulonodules, notably in areas that are accessible to the patient. The pathophysiology is hypothesized to be mediated by a Th2 helper cell response, similar to that seen in atopic dermatitis, therefore, treatment of PN with dupilumab would be expected to elicit a therapeutic response. We demonstrated that treatment of PN with dupilumab significantly decreased pruritis and the size and number of new lesions after 2 months of treatment. J Drugs D...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
Condition:   Seborrheic Dermatitis Intervention:   Drug: ARQ-154 foam or ARQ-154 vehicle Sponsor:   Arcutis, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study investigated the anti-allergic effect of Poncirus trifoliata (L.) Raf. (PT) on human keratinocytic HaCaT cells in vitro and on 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis-like lesions in vivo. The release of TARC, MCP-1, IL-6 and IL-8 is increased by IFN-γ and TNF-α in HaCaT cells, and PT extract suppressed the increased production of TARC, MCP-1, IL-6, and IL-8. PT extract recovered the expression of filaggrin decreased by IFN-γ and TNF-α. in vivo experiment, PT administration decreased the skin severity score, thickening of the epidermis, movement of inflammatory cells int...
Source: International Journal of Medical Sciences - Category: Biomedical Science Tags: Int J Med Sci Source Type: research
Atopic Dermatitis (AD) is an inflammatory skin disease associated with increased levels of type 2 cytokines. In addition, the skin of AD patients is frequently colonized with Staphylococcus aureus and increased levels of this pathogen are associated with increased disease severity and elevated type 2 allergic responses (Leung et al., 2019). Recent studies have also shown that the onset of S. aureus colonization correlates with the onset of type 2 responses (Meylan et al., 2017, Nakatsuji et al., 2016), however, a mechanism to explain the induction of type 2 responses by S.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Letters to the Editor Source Type: research
Condition:   Stasis Dermatitis Interventions:   Drug: crisaborole ointment;   Other: vehicle ointment Sponsor:   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Atopic Dermatitis Interventions:   Drug: ASLAN004;   Drug: ASLAN004 Placebo Sponsor:   Aslan Pharmaceuticals Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Stasis Dermatitis Interventions:   Drug: crisaborole ointment;   Other: vehicle ointment Sponsor:   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Atopic Dermatitis Interventions:   Drug: ASLAN004;   Drug: ASLAN004 Placebo Sponsor:   Aslan Pharmaceuticals Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Children | Dermatitis | Dermatology | Skin